| |
| |
|
| Insider
Information: |
Bishop Hans Edgar |
| Relationship: |
Director |
| City: |
Seattle |
| State: |
WA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
10,734,769 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$16,077,755 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
10,734,769 |
|
|
| Total
Value |
$16,077,755 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Dendreon Corp |
DNDN |
Chief Operating Officer |
2011-07-29 |
151,189 |
2010-01-29 |
0 |
Premium* |
|
|
Avanir Pharmaceuticals |
AVNR |
Director |
2014-02-12 |
93,350 |
2013-02-14 |
0 |
Premium* |
|
|
Juno Therapeutics, Inc. |
JUNO |
CEO & President, Direc... |
2018-03-05 |
0 |
|
0 |
Premium* |
|
|
Agilent Technologies Inc |
A |
Director |
2024-03-15 |
24,976 |
2017-07-18 |
0 |
Premium* |
|
|
Celgene Corp |
CELG |
|
2019-11-20 |
0 |
2019-11-20 |
0 |
Premium* |
|
|
Sana Biotechnology, Inc. |
SANA |
|
2024-04-05 |
5,779,640 |
|
0 |
Premium* |
|
|
Lyell Immunopharma, Inc. |
LYEL |
Director |
2022-09-08 |
4,685,614 |
2021-06-21 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
62 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CELG |
Celgene Corp |
|
– • – |
2019-11-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(23,088) |
0 |
0 |
- |
|
| SANA |
Sana Biotechnology, Inc. |
|
– • – |
2022-04-05 |
4 |
A |
$0.00 |
$0 |
D/D |
2,880 |
5,739,130 |
0 |
- |
|
| SANA |
Sana Biotechnology, Inc. |
|
– • – |
2022-07-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,328 |
5,742,458 |
0 |
- |
|
| SANA |
Sana Biotechnology, Inc. |
|
– • – |
2022-10-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,012 |
5,746,470 |
0 |
- |
|
| SANA |
Sana Biotechnology, Inc. |
|
– • – |
2023-04-05 |
4 |
A |
$0.00 |
$0 |
D/D |
7,716 |
5,760,888 |
0 |
- |
|
| SANA |
Sana Biotechnology, Inc. |
|
– • – |
2023-07-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,152 |
5,765,040 |
0 |
- |
|
| SANA |
Sana Biotechnology, Inc. |
|
– • – |
2023-10-05 |
4 |
A |
$0.00 |
$0 |
D/D |
6,925 |
5,771,965 |
0 |
- |
|
| SANA |
Sana Biotechnology, Inc. |
|
– • – |
2024-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,901 |
5,776,866 |
0 |
- |
|
| SANA |
Sana Biotechnology, Inc. |
|
– • – |
2024-04-05 |
4 |
A |
$0.00 |
$0 |
D/D |
2,774 |
5,779,640 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-06-09 |
4 |
OE |
$6.36 |
$343,440 |
D/D |
54,000 |
2,704,609 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-06-09 |
4 |
AS |
$45.80 |
$4,212,344 |
D/D |
(90,750) |
2,613,859 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-06-30 |
4/A |
AS |
$38.41 |
$4,431,116 |
D/D |
(115,250) |
2,542,609 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-06-30 |
4 |
D |
$38.41 |
$4,431,116 |
D/D |
(115,250) |
2,542,609 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-06-30 |
4 |
OE |
$6.36 |
$279,840 |
D/D |
44,000 |
2,657,859 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-08-31 |
4 |
AS |
$30.06 |
$1,282,554 |
D/D |
(42,673) |
2,518,109 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-08-31 |
4 |
OE |
$6.36 |
$115,580 |
D/D |
18,173 |
2,560,782 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-09-08 |
4 |
OE |
$6.36 |
$146,547 |
D/D |
23,042 |
2,541,151 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-09-08 |
4 |
AS |
$30.06 |
$692,578 |
D/D |
(23,042) |
2,518,109 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-09-19 |
4 |
OE |
$6.36 |
$2,722 |
D/D |
428 |
2,518,537 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-09-19 |
4 |
AS |
$30.00 |
$12,840 |
D/D |
(428) |
2,518,109 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-09-20 |
4 |
OE |
$6.36 |
$40,068 |
D/D |
6,300 |
2,524,409 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-09-20 |
4 |
AS |
$30.00 |
$189,003 |
D/D |
(6,300) |
2,518,109 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-09-21 |
4 |
OE |
$6.36 |
$38,523 |
D/D |
6,057 |
2,524,166 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-09-21 |
4 |
AS |
$30.30 |
$2,342,588 |
D/D |
(77,307) |
2,446,859 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-09-27 |
4 |
AS |
$33.00 |
$1,452,000 |
D/D |
(44,000) |
2,446,859 |
0 |
- |
|
62 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
